Taiwan Bio Therapeutics (ROCO:6892) LT-Debt-to-Total-Asset: 0.21 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
22 GF Score
Price NT$26.70
GF Value NT$14.65
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics LT-Debt-to-Total-Asset?

Taiwan Bio Therapeutics ROCO:6892 -0.74% 22 LT-Debt-to-Total-Asset is 0.21 as of Dec. 2025. GuruFocus rates ROCO:6892 with a GF Score™ of 22/100 and a GF Value™ of NT$14.65 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Taiwan Bio Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.21.

Taiwan Bio Therapeutics's long-term debt to total assets ratio declined from Sep. 2024 (0.22) to Dec. 2025 (0.21). It may suggest that Taiwan Bio Therapeutics is progressively becoming less dependent on debt to grow their business.

Taiwan Bio Therapeutics  (ROCO:6892) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Taiwan Bio Therapeutics LT-Debt-to-Total-Asset Related Terms

Taiwan Bio Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Taiwan Bio Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics LT-Debt-to-Total-Asset Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.47 0.31 0.27 0.19 0.21

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.19 0.22 0.23 0.21
ROCO:6892
22GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Bio Therapeutics LT-Debt-to-Total-Asset Calculation

Taiwan Bio Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=282.966/1354.718
=0.21

Taiwan Bio Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=282.966/1354.718
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.21 mean?
Taiwan Bio Therapeutics (ROCO:6892) has a LT-Debt-to-Total-Asset of 0.21 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Taiwan Bio Therapeutics and its competitors.
Is Taiwan Bio Therapeutics' LT-Debt-to-Total-Asset too high?
Taiwan Bio Therapeutics' current LT-Debt-to-Total-Asset is 0.21. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Taiwan Bio Therapeutics' LT-Debt-to-Total-Asset of 0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Taiwan Bio Therapeutics and its competitors. Taiwan Bio Therapeutics's current LT-Debt-to-Total-Asset is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.65, compared to a current price of NT$26.70 — trading 82.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.21. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current LT-Debt-to-Total-Asset is 0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$26.70 is trading 82.3% above its estimated GF Value™ of NT$14.65. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • LT-Debt-to-Total-Asset: 0.21
  • GF Value™: NT$14.65 vs. price of NT$26.70 (82.3% above fair value)
  • GF Score™: 22/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score

Get the complete analysis for ROCO:6892

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.70
Price
NT$14.65
GF Value